Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Proprietary compound preparation BNF 1003020
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Pernaton Warming gel
100302000BBBXA0
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | 1 |
|
Balsamka muscle balm
100302000BBAWA0
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | No data available |
|
Dulbalm cream
100302000BBBWA0
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | No data available |
|
Intralgin gel
100302000BBBBAA
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | No data available |
|
Salonpas medicated plasters
100302000BBBTA0
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | No data available |
|
Tiger Balm Red ointment
100302000BBBMA0
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | No data available |
|
Tiger Balm White ointment
100302000BBBPA0
|
Proprietary compound preparation BNF 1003020 | Other rubefacient and topical antirheumatic preparations | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.